1. Home
  2. SNCR vs BOLD Comparison

SNCR vs BOLD Comparison

Compare SNCR & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Synchronoss Technologies Inc.

SNCR

Synchronoss Technologies Inc.

HOLD

Current Price

$8.55

Market Cap

59.5M

Sector

Technology

ML Signal

HOLD

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

HOLD

Current Price

$1.20

Market Cap

26.2M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNCR
BOLD
Founded
2000
2018
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
59.5M
26.2M
IPO Year
2006
2024

Fundamental Metrics

Financial Performance
Metric
SNCR
BOLD
Price
$8.55
$1.20
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.00
AVG Volume (30 Days)
288.0K
144.6K
Earning Date
11-04-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$170,909,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.37
N/A
P/E Ratio
N/A
N/A
Revenue Growth
0.07
N/A
52 Week Low
$3.98
$1.00
52 Week High
$12.85
$3.12

Technical Indicators

Market Signals
Indicator
SNCR
BOLD
Relative Strength Index (RSI) 75.14 51.20
Support Level $8.39 $1.17
Resistance Level $8.50 $1.37
Average True Range (ATR) 0.12 0.08
MACD -0.05 0.01
Stochastic Oscillator 86.84 32.00

Price Performance

Historical Comparison
SNCR
BOLD

About SNCR Synchronoss Technologies Inc.

Synchronoss Technologies Inc is a provider of white-label cloud, messaging, digital and network management solutions that enable its customers to keep subscribers, systems, networks and content in sync. The Synchronoss Personal CloudTM solution is designed to create an engaging and trusted customer experience through ongoing content management and engagement. The Synchronoss Personal CloudTM platform is a secure and scalable, white-label platform that allows its customers' subscribers to backup and protect, engage with, and manage their personal content. The company derives revenue from subscriptions and transaction-based fees. A majority of the firm's revenue is generated in the United States, and the rest is from countries across the world.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

Share on Social Networks: